You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Amos Gilhar

From EverybodyWiki Bios & Wiki







Amos Gilhar
Amos GilharAmos Gilhar.png Amos Gilhar.png
Native nameעמוס גילהר
Born(1947-08-11)August 11, 1947
Haifa
🏳️ CitizenshipIsraeli
🎓 Alma materRuth and Bruce Rapaport Faculty of Medicine of the Technion-Israel Institute of Technology
💼 Occupation
🏢 OrganizationRuth and Bruce Rapaport Faculty of Medicine of the Technion-Israel Institute of Technology
👩 Spouse(s)Dorit
🏅 Awards2006: EM Farber Research Award for Excellence in Research, Society for Investigative Dermatology, USA
🌐 Websiterbni.technion.ac.il/node/179
🥚 TwitterTwitter=
label65 = 👍 Facebook

Amos Gilhar is an Israeli dermatologist, professor emeritus at the Ruth and Bruce Rapaport Faculty of Medicine, Technion-Israel Institute of Technology.[1] He is the second director of Flieman Medical Center, Haifa (1994–2016).[2] Gilhar is founder and Head of the Skin Research Laboratory, Faculty of Medicine, Technion- Israel Institute of Technology, Haifa since 1986.[3]

Biography[edit]

Amos Gilhar was born on 11 August 1947 in Haifa. He graduated the Hebrew Reali School, Haifa in 1965 and the Faculty of Medicine, Technion, Haifa in 1976 (MD).[3] After graduation he served in the army as airborne physician.

Medical career[edit]

Prof. Gilhar completed his residency in Dermatology at Rambam Medical Center in 1982. At the same time he specialized in immunodermatology in the laboratory of Dr. Dov Golan, Faculty of Medicine, Technion. In 1982-1984 he served as a senior dermatologist at Rambam Medical Center.

In 1984-1985, he did his fellowship at Utah University in Salt Lake City, Utah, USA, headed by Prof. Gerald Kreuger.

From 1994 to 2016, Gilhar served as Director of the Flieman Medical Center in Haifa.[4][5]

In 1986 Prof. Gilhar founded the Skin Research Laboratory at the Faculty of Medicine, Technion, Haifa.[6][3]

Research[edit]

The Skin Research Laboratory has been established in 1986 and since its inception has been headed by Prof Amos Gilhar. The laboratory is based mainly on the "humanized” mice, which are defined as immunodeficient mice that are xenotransplanted with relevant functional human biological systems, i.e. human full-thickness skin (with all its skin appendages) injected with immune cells from the same donor.

Over the past decade, Prof Gilhar has been conscientiously making improvements on the development of humanized mice as a model to closely recapitulate disease pathogenesis and drug mechanisms in humans. The skin humanized mouse models, which were developed in his laboratory, provide opportunities to advance medical skin research. However, it's obvious that a mouse model that completely mimics every single human disease does not exist and each of the skin humanized mice presents advantages and disadvantages.

Prof. Gilhar and his colleagues developed humanized models for the following diseases:

  1. Alopecia Areata (AA),[7][8] which is one of the most common human autoimmune diseases and is characterized by sudden, often persisting and psychologically devastating hair loss.
  2. Androgenic alopecia.[9]
  3. Psoriasis.[10][11]
  4. Atopic dermatitis.[12]
  5. Aged skin.[13]

The main findings of Prof. Gilhar and his colleagues are as follows:

  • in Alopecia Areata:
    • The disease is mediated by T-lymphocyte[7] and can be promoted by injection of T cells activated by skin cell that produces the protective skin-darkening pigment melanin named melanocyte.[14]
    • JAK inhibitor (tofacitinib) exerts beneficial effects in humanized mouse model of alopecia areata.[15] The JAKs are a subgroup of non-receptor tyrosine kinases that transduce signals specifically from cytokine receptors, and whose enzymatic activity is essential for the biological activity of cytokines.
  • In psoriasis:
    • Therapeutic effect of cAMP phosphodiesterase-4 inhibitor,[11] blocking of interleukin IL-17,[16] TNF-α and various other immune components were observed in the humanized mouse model for psoriasis.[17]
    • Non –conventional immune cell named innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin.[18]
  • In aged skin:
    • Reversal of some skin changes[19]
    • Vascular endothelial growth factor (VEGF) mediates rejuvenation of aged human skin xenografts in young mice[20]
Amos Gilhar - Farber Research Award

Prof. Gilhar collaborated with scientists such as the late Prof. Richard Kalish, Chair, Department of Dermatology, Stony Brook University Hospital, USA and during the last two decades with Prof. Ralf Paus from University of Miami Miller School of Medicine, Miami, FL, USA and University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, UK.[21]

In 2006 Gilhar won the EM Farber Research Award for Excellence in Research, Society for Investigative Dermatology, USA.

Public sector career[edit]

Since 2016, Prof. Gilhar has been a member of the scientific advisory board of the National Alopecia Areata Foundation (NAAF), California.[22]

In 1996–2012, he was a member of the advisory board of the Cosmetics Licensing Authority of the Israeli Ministry of Health and during 2005–2007 he was chairman of the committee for regulation of aesthetic non-surgical medical treatments.[23]

Since 2011, he has been a member of the editorial board of Experimental Dermatology, a scientific journal published in Germany[24]

Publications[edit]

Prof. Gilhar has signed over 150 original studies, most of them in basic research[25]

See also[edit]

References[edit]

  1. "Professor Emeritus Amos Gilhar". Technion-Israel Institute of Technology. Retrieved 16 July 2020.
  2. "Farewell evening from Professor Gilhar". Fliman Gariatric Center. Retrieved 16 July 2020.
  3. 3.0 3.1 3.2 "Technion - Israel Institute of Technology, Israel - Amos Gilhar's Lab". Labnesium. Retrieved 16 July 2020.
  4. "חיים יותר - פורשים פחות" – via TheMarker.
  5. "הפתרון נמצא בביה"ח הגריאטריים" – via TheMarker.
  6. Amos Gilhar (20 May 2019). Israeli researchers discover unknown factor in psoriasis. Haaretz.
  7. 7.0 7.1 Gilhar A, Ullmann Y, Berkutzki T, Assy B, and Kalish RS. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998; 101:62–7.
  8. Gilhar A, Keren A, Shemer A, d’Ovidio R, Ullmann Y, Paus R. Autoimmune Disease Induction in a Healthy Human Organ: A Previously Unreported Humanized Mouse Model of Alopecia Areata. J Invest Dermatol
  9. Sintov A, Serafimovich S, and Gilhar A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. Int J Pharm 2000;194:125–34.
  10. Gilhar, A. Keren A, Paus R. Which characteristics does an optimal animal model for psoriasis need to show? J Invest Dermatol 139(5), Supplement, A1–A6, S1-S214, 2019.
  11. 11.0 11.1 Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A., Cheung YF. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842–55.
  12. Keren A, Ullmann Y, Riethmüller C, Paus R, Gilhar, A. Development of a novel humanized mouse model for atopic dermatitis. J Invest Dermatol 2019;139(5):S114.
  13. Gilhar A, Pillar T, David M, and Eidelman S. Melanocytes and Langerhans cells in aged versus young skin before and after transplantation onto nude mice. J Invest Dermatol 1991;96:210–14
  14. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, and Kalish RS. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 2001; 117:1357–62.
  15. Laufer Britva R, Keren A, Paus R, Gilhar A. Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata. Br J Dermatol. 2020;182:227–229.
  16. Zaretsky M, Etzyoni R, Kaye J, Sklair-Tavron L, Aharoni A Directed evolution of a soluble human IL-17A receptor for the inhibition of psoriasis plaque formation in a mouse model. J Chem Biol. 2013 ;20 :202-11
  17. Hecht I, McNamee K, Keren A, Podojil JR, Vaknin I, Oren I, Rotman G, Neria E, Miller SD, Gilhar A, Williams RO. CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis. 2014, American College of Rheumatology. Boston, MA, USA.
  18. Keren A, Shemer A, Ginzburg A, Ullmann Y, Schrum AG, Paus R, Gilhar A. Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. J Allergy Clin Immunol. 2018 : S0091–6749.
  19. Gilhar A, Ish-Shalom S, Pillar T, et al. Effect of anti-insulin-like growth factor on epidermal proliferation of human skin transplanted onto nude mice treated with growth hormone. Endocrinology. 1994; 134:229–232.
  20. VEGF mediates rejuvenation of aged human skin xenografts in young mice" 9th International Conference on Skin Ageing and Challenges, Porto, Portugal, February, 2018
  21. "Scientific Advisory Board – Hair growth". Follicum. Retrieved 16 August 2020.
  22. "Research Advisory Councils". National Alopecia Areata Foundation. Retrieved 10 August 2020.
  23. "member of the advisory board of the Cosmetics Licensing Authority". Israeli Ministry of Health. Retrieved 10 August 2020.
  24. "Editorial Information". Experimental Dermatology. Retrieved 10 August 2020.
  25. "Amos Gilhar's research". SemanticScholar. Retrieved 16 July 2020.
    "Amos Gilhar's research". PubFacts. Retrieved 16 July 2020.
    "Amos Gilhar research". Researchgate. Retrieved 16 July 2020.

External links[edit]


This article "Amos Gilhar" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Amos Gilhar. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.